空间蛋白质组学揭示SIRT1是人黑色素瘤T细胞浸润的决定因素
研究通过空间蛋白质组学比较黑色素瘤中T细胞浸润高低区域,发现SIRT1等145种以上蛋白在CD8高表达区富集;小鼠模型中药物激活SIRT1增强α-PD-1疗效并增加T细胞浸润;SIRT1与趋化因子及患者生存正相关。
要点
- SIRT1在CD8高浸润肿瘤区域表达更高。
- 药物激活SIRT1增强α-PD-1抗黑色素瘤效果。
- SIRT1与CXCL9、CXCL10、IFN-γ正相关并关联生存。
核心结论
- SIRT1是决定黑色素瘤T细胞浸润的关键蛋白,具有预后和治疗意义。
研究设计与样本
- 研究结合显微镜、MALDI质谱成像和液相色谱-质谱联用及计算数据挖掘,绘制黑色素瘤T细胞浸润高低区域的空间蛋白分布。
- 在两种同基因小鼠黑色素瘤模型中药物调节SIRT1活性,其一已知对α-PD-1敏感,另一对α-PD-1耐药。
主要发现
- 空间蛋白质组学和基因本体富集分析鉴定出CD8高表达肿瘤区域富集超过145种蛋白,包括mTOR信号负调节因子SIRT1。
- 多重免疫组化证实SIRT1蛋白在CD8高表达区域比CD8低表达区域表达更多。
- 小鼠体内实验显示药物激活SIRT1增强α-PD-1对黑色素瘤的免疫效果,伴随T细胞浸润及IFN-γ、CCL4、CXCL9、CXCL10、TNF-α等T细胞相关细胞因子增加。
- 大规模转录数据计算机分析显示SIRT1与促炎T细胞趋化因子CXCL9、CXCL10和IFN-γ正相关,并与黑色素瘤患者总生存期延长相关。
临床怎么用
- SIRT1表达或可作为黑色素瘤免疫检查点抑制疗效的预测标志物。
- 药物激活SIRT1可能成为增强α-PD-1疗效的联合治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tumour microenvironment significantly influences the clinical response of patients to therapeutic immune checkpoint inhibition (ICI), but a comprehensive understanding of the underlying immune-regulatory proteome is still lacking. OBJECTIVES: To decipher targetable biologic processes that determine tumour-infiltrating lymphocytes (TiLs) as a cellular equivalent of clinical response to ICI. METHODS: We mapped the spatial distribution of proteins in TiL-enriched vs. TiL-low compartments in melanoma by combining microscopy, matrix-assisted laser desorption mass spectrometry imaging and liquid chromatography-mass spectrometry, as well as computational data mining. Pharmacological modulation of sirtuin 1 (SIRT1) activity in syngeneic mouse models was used to evaluate the efficacy of pharmacological SIRT1 activation in two syngeneic melanoma mouse models, one known to be α-programmed cell death protein 1 (PD-1) sensitive and the other α-PD-1 resistant. RESULTS: Spatial proteomics and gene ontology-based enrichment analysis identified > 145 proteins enriched in CD8high tumour compartments, including negative regulators of mammalian target of rapamycin signalling such as SIRT1. Multiplexed immunohistochemistry confirmed that SIRT1 protein was expressed more in CD8high than in CD8low compartments. Further analysis of bulk and single-cell RNA sequencing data from melanoma tissue samples suggested the expression of SIRT1 by different lymphocyte subpopulations (CD8+ T cells, CD4+ T cells and B cells). Furthermore, we showed in vivo that pharmacological SIRT1 activation increased the immunological effect of α-PD-1 ICI against melanoma cells in mice, which was accompanied by an increase in T-cell infiltration and T-cell-related cytokines, including interferon (IFN)-γ, CCL4, CXCL9, CXCL10 and tumour necrosis factor-α. In silico analysis of large transcriptional data cohorts showed that SIRT1 was positively associated with the proinflammatory T-cell chemokines CXCL9, CXCL10 and IFN-γ, and prolonged overall survival of patients with melanoma. CONCLUSIONS: Our study deciphers the proteomics landscape in human melanoma, providing important information on the tumour microenvironment and identifying SIRT1 as having important prognostic and therapeutic implications. The area around a tumour has a big impact on how patients with a type of skin cancer called melanoma respond to treatment called ‘immune checkpoint inhibition’ (or ‘ICI’ for short). We still do not fully understand all the proteins in the immune system. In this study, we wanted to understand the biological processes that affect patients’ responses to ICI. Using different laboratory techniques and analysing data, we studied the proteins in melanoma. We found more than 145 proteins in certain tumour areas, including a protein called ‘SIRT1’. SIRT1 slows down a particular signalling pathway in cells. Further analysis suggested that SIRT1 was expressed by different types of immune cells. In mice, we found that activating SIRT1 increased the anti-tumour effect of ICI. Data analysis showed that SIRT1 is positively associated with the increased survival of patients with melanoma. Our study explores the proteins involved in human melanoma. It provides important information on the tumour microenvironment. It also shows that the protein SIRT1 could be important for predicting outcomes and guiding treatment.
引用
- Placke JM, Bottek J, Váraljai R, et al. Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma. Br J Dermatol. 2025. PMID: 39739311. doi:10.1093/bjd/ljae433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。